bioMérieux S.A. (BMXXY) Stock

About bioMérieux S.A.

bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. Its operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides sophisticated diagnostic platforms that analyze biological specimens to pinpoint infectious diseases, cardiovascular conditions, and various cancers. Additionally, it offers microbiological testing for quality control in manufacturing, serving the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele encompasses clinical and hospital laboratories, medical practitioners, blood banks, and industrial control facilities. Founded in 1963, the company, previously known as B-D Mérieux, maintains its headquarters in Marcy l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

bioMérieux S.A. is headquartered in FR.

bioMérieux S.A. (BMXXY) stock trades at $7.60 with a market capitalization of $8.96B. The stock is valued at a price-to-earnings (P/E) ratio of 21.32, price-to-book of 2.06, price-to-sales of 2.08. Over the past 52 weeks the stock has ranged between $7.12 and $14.62, and currently trades 48.0% below its 52-week high. It pays a dividend yielding 1.45%.

On profitability, bioMérieux S.A. generates a return on equity (ROE) of 9.89%, return on capital employed of 8.61%, an operating margin of 9.54%, a net profit margin of 9.76%.

Official website: www.biomerieux.com

bioMérieux S.A. by the numbers, 2016–2025

Between 2016 and 2025 bioMérieux S.A. reported revenue of $2.1B rising to $4.1B, a change of +93.5% across 10 years. Compounded, revenue has grown 5.5% a year over five years, 4.3% over three, 2.3% over the last twelve months. Net profit rose to $382.0M.

Operating margin went from 11.5% in 2016 to 17.1% in 2025, a gain of 5.6 percentage points. The most recent net margin is 9.76%. On a trailing twelve-month basis to Dec '25, revenue is $8.0B and net profit $828.0M.

Borrowings held roughly flat from $453.0M to $461.0M, cash on hand is $569.6M, cash from operations was $757.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 12.2% over five years, and was 9.3% in the most recent year.

The share price itself has compounded at —% a year over five years, -6.2% over three, -44.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

bioMérieux S.A. (BMXXY) — frequently asked questions